Reunion Neuroscience
Latest round
- Series A
Last raised
- May 2024
Total raised
- $103M
Investors
- 7
About Reunion Neuroscience
, operates as a clinical-stage biopharmaceutical company that develops and patents therapeutic solutions for the mental health industry. In May 2023, MPM Capital agreed to acquire Reunion Neuroscience Inc.12 per share in a public-to-private transaction. The company offers various pharmaceutical solutions that include novel psychedelic compounds used for the treatment of psychiatric conditions, including depression. The serotonergic psychedelic compound is used to generate serotonergic receptors in the brain, regulating mood, appetite, sleep, learning, memory, and many other biological and physiological functions, hence acting as an antidepressant for patients. The company plans to get delisted from the NASDAQ stock exchange.
Who invested in Reunion Neuroscience
7 investors across 1 round
See all investors in Reunion Neuroscience
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 2, 2024
Amount
$103M
Investors
Questions about Reunion Neuroscience
Who invested in Reunion Neuroscience?
Reunion Neuroscience has 7 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Reunion Neuroscience raised?
Reunion Neuroscience has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Reunion Neuroscience last raise money?
Reunion Neuroscience's most recent round on record is a Series A, in May 2024.
What does Reunion Neuroscience do?
, operates as a clinical-stage biopharmaceutical company that develops and patents therapeutic solutions for the mental health industry.
Where is Reunion Neuroscience headquartered?
Reunion Neuroscience is headquartered in Toronto, Canada.
Which VCs invest in companies like Reunion Neuroscience?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Reunion Neuroscience's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Reunion Neuroscience? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.